Skip to content
Primary Menu
Technology
Clinical Data
Pipeline
About
Media
Contact
Media
News
Press
16/12/2024
ENEA-Tech Biomedical Foundation Invests €6m in BetaGlue® Therapeutics Bringing 2024 Funding Round Total to €24m
News
Press
06/06/2024
BetaGlue® Adds €8m Equity Financing to €10m EIC Accelerator Award
News
Press
15/05/2024
BetaGlue® Therapeutics Announces the Appointment of Mike Cogswell as Chairman and Mike Maszy as Non-Executive Director
News
Press
30/04/2024
BetaGlue® Technologies SpA Announces Rebrand & Introduces YntraDose®
News
Press
04/03/2024
BetaGlue® Secures €10m EIC Accelerator Award
News
Press
15/01/2024
BetaGlue® Appoints Salvatore Calabrese as Chief Financial Officer
News
Press
27/02/2023
BetaGlue® renews the BoD: Dr Colin Story appointed CEO
News
20/10/2022
BetaGlue® strengthens its expertise in strategic areas with four new managers
News
03/10/2022
BetaGlue® published an article on the performance and safety of BAT-90 on ‘In Vivo’
News
28/07/2022
BetaGlue® has closed a 10 million euro equity financing round
News
22/07/2022
BetaGlue® has enrolled the first patient treated with BAT-90 in its First-in-Human trials, taking radiotherapy inside solid tumours
News
24/04/2020
BetaGlue® Technologies announces new Board of Directors
